Medicare Enrolled
Dr. Youram Nassir, MD
Hematology & Oncology · Los Angeles, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Nassir from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Nassir?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Nassir
Dr. Youram Nassir is a hematology & oncology specialist in Los Angeles, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Nassir performed 246,348 Medicare services across 9,247 unique beneficiaries.
Between the years covered by Open Payments, Dr. Nassir received a total of $24,611 from 95 pharmaceutical and/or device companies across 1366 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Nassir is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 2% volume in CA
$24,611 industry payments
Medicare Practice Summary
Medicare Utilization ↗246,348
Medicare services
Top 2% in CA for hematology & oncology
9,247
Unique beneficiaries
$11
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~12,966 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Oxaliplatin chemotherapy injection This procedure involves the administration of oxaliplatin, a chemotherapy medication, via injection. The dosage specified is 0.5 mg. |
49,630 | $0 | $41 |
| Injection, tbo-filgrastim, 1 microgram | 33,720 | $0 | $25 |
| Anti-nausea injection (ondansetron/Zofran) | 32,493 | $0 | $47 |
| Paclitaxel chemotherapy injection | 17,210 | $0 | $39 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
13,286 | $0 | $39 |
| Filgrastim injection (Zarxio) for white blood cells An injection of the biosimilar medication filgrastim-sndz (Zarxio) with a dosage of 1 microgram. |
10,813 | $0 | $17 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
8,698 | $12 | $256 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
7,100 | $102 | $1,336 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
6,591 | $8 | $88 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
6,505 | $27 | $537 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
6,470 | $0 | $108 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
6,427 | $8 | $152 |
| Basic metabolic blood panel A blood test that measures a group of basic chemicals, including total calcium levels. |
6,016 | $8 | $167 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
5,713 | $109 | $1,423 |
| Liver function blood test panel | 5,363 | $8 | $162 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
4,706 | $1 | $68 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
2,871 | $60 | $1,270 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
2,129 | $2 | $517 |
| Injection, leucovorin calcium, per 50 mg | 1,390 | $3 | $348 |
| Carcinoembryonic antigen (CEA) level test A blood test that measures the level of carcinoembryonic antigen (CEA) protein. This test is used to monitor certain types of cancer. |
1,242 | $19 | $369 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
1,203 | $14 | $259 |
| Injection, potassium chloride, per 2 meq | 1,190 | $0 | $36 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
1,189 | $1 | $45 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
994 | $155 | $1,998 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
982 | $123 | $1,694 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
917 | $12 | $293 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 915 | $3 | $1,000 |
| Hydromorphone injection, up to 4 mg An injection of hydromorphone, an opioid pain medication, with a dosage of up to 4 milligrams. |
896 | $3 | $418 |
| Thyroid stimulating hormone (TSH) test A blood test that measures the level of thyroid stimulating hormone to evaluate thyroid function. |
857 | $16 | $332 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
841 | $26 | $360 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
593 | $6 | $1,950 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
572 | $2 | $540 |
| Lipid panel (cholesterol and triglycerides) A blood test that measures cholesterol and triglyceride levels. |
559 | $13 | $356 |
| Filgrastim injection, 1 microgram An injection of filgrastim, a medication that stimulates the production of white blood cells. This code specifically covers the brand-name drug and excludes biosimilar versions. |
544 | $0 | $14 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
532 | $111 | $1,493 |
| PSA test (prostate cancer screening) | 503 | $18 | $367 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
469 | $19 | $378 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
404 | $61 | $816 |
| Cisplatin chemotherapy injection, 10 mg Administration of a 10 mg dose of cisplatin, a chemotherapy medication, via injection. |
391 | $2 | $138 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
374 | $30 | $959 |
| Magnesium sulfate injection, per 500 mg An injection of magnesium sulfate administered in 500 mg increments. |
358 | $1 | $198 |
| IV chemotherapy initiation with community continuation Initiation of an intravenous chemotherapy infusion in a clinic using clinic supplies, with continuation of the infusion in a community setting such as home or assisted living. |
344 | $159 | $5,559 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
291 | $1 | $195 |
| New patient office visit, complex (60-74 min) | 226 | $188 | $2,435 |
| Electrocardiogram (EKG), 12-lead A standard heart rhythm test using at least 12 leads to record electrical activity. A healthcare provider interprets the results and provides a written report. |
182 | $13 | $202 |
| Refilling and maintenance of portable pump This service involves refilling and performing maintenance on a portable pump. |
182 | $120 | $1,743 |
| Continuous ECG monitoring with transmission and review Continuous electrocardiogram monitoring for up to 30 days with symptom tracking. The data is transmitted and reviewed by a healthcare professional who provides a report. |
162 | $20 | $278 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
154 | $52 | $724 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
154 | $148 | $2,200 |
| Pembrolizumab injection (Keytruda) | 133 | $0 | $0 |
| Total testosterone level test A blood test that measures the total amount of testosterone in your body. This hormone is important for various bodily functions in both men and women. |
103 | $25 | $491 |
| Free testosterone level test A blood test that measures the amount of free testosterone in your body. Free testosterone is the portion of the hormone not bound to proteins and available for use by tissues. |
101 | $25 | $484 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
99 | $31 | $375 |
| Rituximab injection, 10 mg Administration of a 10 mg dose of rituximab medication via injection. |
98 | $45 | $929 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 125 | 96 | $20 | $417 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 75 | $124 | $2,424 |
| Follicle stimulating hormone (FSH) level A blood test to measure the level of follicle stimulating hormone, a reproductive hormone. |
57 | $18 | $353 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
57 | $18 | $241 |
| Luteinizing hormone level test A blood test that measures the level of luteinizing hormone, a reproductive hormone. This test helps evaluate hormonal balance and reproductive function. |
56 | $18 | $354 |
| Nivolumab injection (Opdivo) | 42 | $0 | $0 |
| Prochlorperazine injection, up to 10 mg An injection of prochlorperazine administered in a dose of up to 10 mg. |
34 | $2 | $503 |
| Vitamin D level test A blood test to measure the amount of Vitamin D-3 in your body. |
12 | $29 | $406 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
12 | $80 | $970 |
| Bone marrow aspiration A procedure to remove a small sample of liquid bone marrow for diagnostic testing. |
11 | $72 | $9,269 |
| Biopsy of bone marrow | 11 | $149 | $9,266 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
6.6% high complexity
69.6% medium
23.7% routine
Industry Payment Transparency
Open Payments through 2024 ↗$24,611
Total received (2018-2024)
Avg $3,516/year across 7 years
Top 18% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
95
Companies
1,366
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$24,396 (99.1%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$215 (0.9%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$4,162
2023
$3,719
2022
$3,489
2021
$3,309
2020
$2,340
2019
$3,243
2018
$4,349
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$494
E.R. Squibb & Sons, L.L.C.
$454
PFIZER INC.
$451
Merck Sharp & Dohme LLC
$308
Regeneron Healthcare Solutions, Inc.
$233
Incyte Corporation
$195
Janssen Biotech, Inc.
$186
Daiichi Sankyo Inc.
$134
Gilead Sciences, Inc.
$100
Ipsen Biopharmaceuticals, Inc
$99
Mirati Therapeutics, Inc.
$94
Agios Pharmaceuticals, Inc.
$83
PUMA BIOTECHNOLOGY, INC.
$77
Eisai Inc.
$75
Celgene Corporation
$72
PharmaEssentia USA Corporation
$70
Lilly USA, LLC
$69
Acrotech Biopharma Inc.
$67
Spectrum Pharmaceuticals Inc.
$67
Novartis Pharmaceuticals Corporation
$62
Astellas Pharma US Inc
$61
JAZZ PHARMACEUTICALS INC.
$60
Exelixis Inc.
$59
ADC Therapeutics America, Inc.
$57
Tempus AI, Inc
$56
GENZYME CORPORATION
$56
ABBVIE INC.
$53
Emmaus Medical, Inc.
$49
SpringWorks Therapeutics, Inc.
$44
Aveo Pharmaceuticals, Inc.
$41
Coherus Biosciences Inc.
$40
Stemline Therapeutics Inc.
$38
TerSera Therapeutics LLC
$30
SUN PHARMACEUTICAL INDUSTRIES INC.
$29
SOBI, INC
$22
GlaxoSmithKline, LLC.
$22
Genentech USA, Inc.
$19
Cumberland Pharmaceuticals, Inc.
$19
Azurity Pharmaceuticals, Inc.
$16
Top 3 companies account for 33.6% of 2024 payments
All-time payments by company (2018-2024) ›
E.R. Squibb & Sons, L.L.C.
$2,571
AstraZeneca Pharmaceuticals LP
$2,238
PFIZER INC.
$2,043
Merck Sharp & Dohme Corporation
$1,119
Janssen Biotech, Inc.
$1,112
Novartis Pharmaceuticals Corporation
$962
Genentech USA, Inc.
$955
Incyte Corporation
$892
Ipsen Biopharmaceuticals, Inc
$880
Merck Sharp & Dohme LLC
$816
GENZYME CORPORATION
$809
Astellas Pharma US Inc
$711
Takeda Pharmaceuticals U.S.A., Inc.
$570
Amgen Inc.
$512
Lilly USA, LLC
$424
Seagen Inc.
$369
Regeneron Healthcare Solutions, Inc.
$364
Celgene Corporation
$358
GlaxoSmithKline, LLC.
$352
Daiichi Sankyo Inc.
$347
Kite Pharma, Inc.
$294
Gilead Sciences, Inc.
$285
PUMA BIOTECHNOLOGY, INC.
$261
Heron Therapeutics, Inc.
$258
Teva Pharmaceuticals USA, Inc.
$255
Eisai Inc.
$247
Alexion Pharmaceuticals, Inc.
$231
PharmaEssentia USA Corporation
$205
Karyopharm Therapeutics Inc.
$204
Emmaus Medical, Inc.
$173
Exelixis Inc.
$164
Seattle Genetics, Inc.
$153
Mirati Therapeutics, Inc.
$152
TerSera Therapeutics LLC
$151
Puma Biotechnology, Inc.
$151
ARRAY BIOPHARMA INC
$148
EMD Serono, Inc.
$142
EISAI INC.
$138
Pharmacyclics LLC, An AbbVie Company
$126
Global Blood Therapeutics, Inc.
$124
JAZZ PHARMACEUTICALS INC.
$124
Stemline Therapeutics Inc.
$117
Spectrum Pharmaceuticals Inc.
$112
Agios Pharmaceuticals, Inc.
$105
Blueprint Medicines Corporation
$102
Coherus Biosciences Inc.
$96
TOLMAR Pharmaceuticals, Inc.
$87
Bayer HealthCare Pharmaceuticals Inc.
$82
Deciphera Pharmaceuticals Inc.
$73
Acrotech Biopharma Inc.
$67
ADC Therapeutics America, Inc.
$57
Tempus AI, Inc
$56
Boehringer Ingelheim Pharmaceuticals, Inc.
$56
Myriad Genetic Laboratories, Inc.
$54
ABBVIE INC.
$53
AVEO Pharmaceuticals, Inc.
$50
MEDIVATION FIELD SOLUTIONS LLC
$49
Foundation Medicine, Inc.
$48
Progenics Pharmaceuticals, Inc.
$47
INSYS Therapeutics Inc
$46
SpringWorks Therapeutics, Inc.
$44
Aveo Pharmaceuticals, Inc.
$41
Kyowa Kirin, Inc.
$38
Mylan Institutional Inc.
$37
Rigel Pharmaceuticals, Inc.
$35
Chiesi USA, Inc.
$32
TESARO, Inc.
$32
Clovis Oncology, Inc.
$30
SUN PHARMACEUTICAL INDUSTRIES INC.
$29
TAIHO ONCOLOGY, INC.
$28
Bayer Healthcare Pharmaceuticals Inc.
$27
Fresenius Kabi USA, LLC
$26
Amneal Pharmaceuticals LLC
$26
Janssen Pharmaceuticals, Inc
$26
CTI BioPharma Corp.
$26
SERVIER PHARMACEUTICALS LLC
$25
Nestle HealthCare Nutrition Inc.
$24
Immunomedics, Inc.
$24
Shire North American Group Inc
$23
SOBI, INC
$22
Allergan, Inc.
$22
GE HealthCare
$22
Dova Pharmaceuticals
$21
Jazz Pharmaceuticals Inc.
$21
GE HEALTHCARE
$21
Pharmacyclics LLC, an AbbVie Company
$21
Cumberland Pharmaceuticals, Inc.
$19
Taiho Oncology, Inc.
$18
APO-PHARMA USA, INC.
$17
Azurity Pharmaceuticals, Inc.
$16
Endo Pharmaceuticals Inc.
$16
Sirtex Medical Inc
$15
BeiGene USA, Inc.
$14
Helsinn Therapeutics (U.S.), Inc.
$14
West Therapeutics Development, LLC
$13
Top 3 companies account for 27.8% of all-time payments
Associated products mentioned in payments ›
ABECMA · ADAKVEO · ADCETRIS · AKYNZEO · ALIMTA · ALUNBRIG · AVASTIN · AYVAKIT · Abraxane · Alecensa · Avastin · BALVERSA · BAVENCIO · BELEODAQ · BENDEKA · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Balversa · Bavencio · Blincyto · CABOMETYX · CALQUENCE · CARVYKTI · CINVANTI · CYRAMZA · Cabometyx · DARZALEX · DEFERIPRONE · Doptelet · ELAHERE · ELIGARD · ELIQUIS · ELITEK · EMPLICITI · ENHERTU · ERBITUX · EXKIVITY · Endari · Enhertu · Erleada · FASLODEX · FERRIPROX · FOTIVDA · FOUNDATIONONE · FOUNDATIONONE LIQUID CDX · Folotyn · GAUCHER-DISEASE · GAVRETO · GILOTRIF · GRANIX · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INLYTA · Idhifa · Inrebic · JADENU · JAKAFI · JEMPERLI · KEYTRUDA · KISQALI · KRAZATI · Kadcyla · Kyprolis · LENVIMA · LIBTAYO · LINZESS · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lazanda · Lenvima · MEKINIST · MONJUVI · MYLOTARG · MYRISK · NASCOBAL · NERLYNX · NINLARO · Nerlynx · Neulasta · Nplate · Nubeqa · OGSIVEO · ONTRUZANT · OPDIVO · OPDUALAG · OXBRYTA · Ogivri · Onivyde · Orserdu · PADCEV · PEMAZYRE · PLUVICTO · POTELIGEO · PROMACTA · PYLARIFY · PYRUKYND · Padcev · Perjeta · Phesgo · Pomalyst · QINLOCK · Quzyttir · REBLOZYL · ROLVEDON · RYBREVANT · Rubraca · SANCUSO · SARCLISA · SCEMBLIX · SHINGRIX · SIR-Spheres Microspheres · SOLIRIS · SOMATULINE DEPOT · SPRYCEL · SUSTOL · SUTENT · SYNAGIS · SYNDROS · Somatuline Depot · Stimufend · Stivarga · TAGRISSO · TECENTRIQ · TECVAYLI · TIBSOVO · TUKYSA · Tavalisse · Tecentriq · Trodelvy · Udenyca · VENCLEXTA · VERZENIO · VIVIMUSTA · VYXEOS · Vonjo · Vyloy · XALKORI · XARELTO · XOSPATA · XPOVIO · XT CDX · XTANDI · Xofigo · Xospata · Xtandi · YONSA · Yescarta · ZEJULA · ZENPEP · ZEPZELCA · ZOLADEX · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (99%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
397
Per 100K population
4.0
County median income
$87,760
Nearest hospital
DOCS SURGICAL HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Nassir is a mixed practice specialist, with above-average Medicare volume (top 2% in CA), with low-engagement industry engagement in the top 18% of CA peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Nassir experienced with oxaliplatin chemotherapy injection?
Based on Medicare claims data, Dr. Nassir performed 49,630 oxaliplatin chemotherapy injection services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Nassir receive payments from pharmaceutical companies?
Yes. Dr. Nassir received a total of $24,611 from 95 companies across 1,366 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Nassir's costs compare to other hematology & oncology specialists in Los Angeles?
Dr. Nassir's average Medicare payment per service is $11. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Nassir) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Los Angeles
Browse hematology & oncology specialists in Los Angeles ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology